From The Stage

BioAgilytix appoints Nathan Speicher as Chief Financial Officer

Posted by BioAgilytix / /

Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed Nathan Speicher as Chief Financial Officer.Nate is a seasoned leader with more than 16 years of experience spanning a variety of roles with a particular focus on the biopharmaceutical and pharma services sectors. At BioAgilytix, he is responsible for the strategy, planning and execution of the enterprise’s finance and accounting operations.Before joining BioAgilytix, he was the Chief Financial Officer for…

BioAgilytix appoints Christie Knittel Mabry as new Chief People Officer

Posted by BioAgilytix / /

Durham, NC, June 23, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed Christie Knittel Mabry as Chief People Officer.Christie joins the executive leadership team and will lead the people strategy across the business as well as help to shape and implement the company’s values and an integrated culture throughout the global organization to support its long-term sustainable growth and operational excellence.She joins BioAgilytix after an extensive career working with companies and…

BioAgilytix Appoints Euan Menzies as Chairman and Chief Executive Officer

Posted by BioAgilytix / /

Durham, NC, June 16, 2022 – BioAgilytix Labs, LLC (“BioAgilytix”), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, today announces the appointment, effective immediately, of Euan Menzies as Chairman and CEO. Jim Datin is retiring from his executive management role but will continue to serve as a non-executive member of the Board of Directors.Euan Menzies joins BioAgilytix with significant experience and a proven background as CEO and Chairman of several software and business services companies. Most notably, he was…

[EPISODE 20] Dr. David Johnson Talks Frosted Flakes, Small Molecules, and Pharmacokinetics!

Posted by BioAgilytix / /

On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix San Diego. They discuss how his childhood breakfast cereal formed an interest in science which eventually led to his pursuit of biochemistry and a career in small molecule therapeutics.  David, known as Dr. J to his friends and colleagues, shares his goal of helping people get a better quality of life through his work in the pharmaceutical industry and what it’s like working with small molecule drugs like aspirin or…

Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?

Posted by BioAgilytix / /

Cellular and gene therapies represent a new wave of rational therapeutic design by genetically modifying cells to carry out therapeutic tasks. While gene therapies use nucleic acids, cell therapies involve use of cellular material to replace missing functional proteins or alter cellular networks responsible for a diseased state. An increased understanding of disease-associated biological pathways and our ability to genetically encode cell and gene therapeutic programs have made treating monogenic disorders and hematological malignancies possible over the past two decades.DOWNLOAD NOW

BioAgilytix appoints top healthcare executive David King to its Board of Directors

Posted by BioAgilytix / /

Durham, NC, May 9, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed top healthcare executive David King to its Board of Directors.Mr. King brings with him more than 20 years of leadership and operational experience in the life sciences and healthcare sectors. He joins BioAgilytix as the CRO embarks on a major expansion of its services including the creation of hundreds of new scientific roles across the company.Mr. King is the…

BioAgilytix Appoints Two New Scientific Officers

Posted by BioAgilytix / /

Durham, NC, May 4, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed two new scientific officers.Lynn Kamen and Michelle Miller bring with them more than two decades of experience combined in drug discovery, development and immunology and toxicology.The addition of Kamen and Miller to the Scientific Office brings the total number on that team to five.Jim McNally, Chief Scientific Officer at BioAgilytix, said: “We are delighted to welcome Lynn and Michelle to our…

[EPISODE 19] Tricia Sterling Talks Rare Diseases, Trust, and Advocacy

Posted by BioAgilytix / /

In this episode of Molecular Moments, Dr. Jim McNally chats with Tricia Sterling, Vice President of Patient Affairs at Aeglea. Tricia shares some of her experiences working with patients in the biotech industry for over a decade. Jim and Tricia’s discussion focuses on the patient side of pharmaceutical research, particularly in relation to rare diseases, as they affect 1 out of 15 people worldwide. They discuss the patient journey, creating better clinical trial experiences, and the importance of giving families hope. Tricia shares how patient advocacy starts with transparency and…